Khondrion is a clinical-stage biopharmaceutical company discovering and developing therapies targeting primary mitochondrial disease. The company is advancing its proprietary science through a wholly-owned clinical and preclinical small molecule pipeline of potential medicines.
The company’s in-house discovery engine is using unique live-cell imaging technologies and predictive disease models to build a portfolio of promising compounds. Active discovery programmes are underway developing new therapies, biomarkers and new read-out technologies in the field of primary mitochondrial diseases.
To accelerate the discovery and development of its potential medicines for mitochondrial diseases, Khondrion collaborates with a global clinical and academic network and patient organisations internationally.
Sonlicromanol, Khondrion’s most advanced product is currently being evaluated in an international multi-center phase 2b clinical trial and an open label extension study in adult patients. A phase 2 study in children is recruiting.
